Table 1. Assessment of histological and qPCR nodal involvement.
| LN/patient | HPN+ | CK19 | HPV16 | MUC1 | HER1 | HER2 | HER3 | VEGF | VEGFC | uPA | MMP9 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 | 3 | 3 | 1 | 2 | 1 | 1 | 1 | 2 | 2 | 0 | 1 |
| 7 | 2 | 3 | 2 | 5 | 0 | 1 | 2 | 1 | 3 | 2 | 1 |
| 16* | 1 | 1 | 0* | 2 | 4 | 0 | 4 | 4 | 4 | 2 | 1 |
| 15 | 7 | 6 | 9 | 9 | 3 | 5 | 4 | 6 | 5 | 3 | 6 |
| 9 | 0 | 0 | 0 | 4 | 5 | 6 | 4 | 5 | 3 | 1 | 1 |
| 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| 5* | 0 | 0 | 0* | 1 | 0 | 1 | 1 | 0 | 4 | 4 | 1 |
| 11 | 2 | 1 | 4 | 4 | 11 | 7 | 5 | 8 | 9 | 8 | 2 |
| 4 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 0 | 0 | 0 |
| 7* | 0 | 0 | 0* | 4 | 4 | 4 | 3 | 4 | 2 | 3 | 5 |
| 6 | 0 | 0 | 0 | 2 | 2 | 4 | 3 | 1 | 1 | 3 | 0 |
| 6 | 0 | 0 | 0 | 5 | 5 | 4 | 3 | 2 | 1 | 1 | 1 |
| 7 | 0 | 0 | 1 | 1 | 1 | 2 | 1 | 0 | 0 | 1 | 0 |
| 8 | 0 | 0 | 0 | 2 | 4 | 4 | 3 | 5 | 5 | 3 | 3 |
| 12 | 0 | 0 | 2 | 6 | 1 | 2 | 2 | 1 | 1 | 1 | 0 |
| 13* | 0 | 0 | 0* | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 8 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 1 | 1 | 1 | 0 |
| 11 | 0 | 0 | 0 | 0 | 2 | 1 | 2 | 1 | 1 | 1 | 2 |
| 10* | 0 | 0 | 0* | 0 | 0 | 0 | 1 | 1 | 2 | 1 | 10 |
| 7 | 0 | 0 | 0 | 3 | 1 | 1 | 2 | 1 | 1 | 4 | 4 |
| 6* | 0 | 0 | 0* | 1 | 0 | 0 | 0 | 2 | 0 | 2 | 5 |
All individual LNs (n = 179) collected from the 21 patients included in this study were assessed for metastatic involvement using histology (HPN+) and the indicated qPCR molecular cancer biomarkers. The total number of LNs collected for each individual patient (LN/patient) is indicated in the first column, followed in each row by the number of LNs found positive for metastatic nodal involvement using the indicated assessment methods (histology or qPCR cancer biomarkers). *Denotes patients with HPV16-E6–negative primary cervical tumors.